It appears that 5-LOX pathway inhibitors have an inhibitory effect on the adhesion of CLL cells to stromal cells, albeit to varying degrees for different samples, and the pattern of efficacy for the different samples differs to that of ibrutinib. This evidence concerns the gene ALOX5 and B-cell chronic lymphocytic leukemia.